We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Pliant Therapeutics Inc (PLRX) USD0.0001

Sell:$11.14 Buy:$14.69 Change: $0.67 (5.00%)
Market closed |  Prices as at close on 24 May 2024 | Switch to live prices |
Change: $0.67 (5.00%)
Market closed |  Prices as at close on 24 May 2024 | Switch to live prices |
Change: $0.67 (5.00%)
Market closed |  Prices as at close on 24 May 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Pliant Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. Its lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The Company has initiated BEACON-IPF, a Phase 2b trial of bexotegrast in IPF. It has also developed PLN-1474, a small molecule, selective inhibitor of αvß1 integrin for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis. It has initiated a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. The Company has a preclinical program, PLN-101325, targeting muscular dystrophies.

Contact details

260 Littlefield Avenue, Suite 150
United States
+1 (650) 4816770

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$767.95 million
Shares in issue:
60.33 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Bernard Coulie
    President, Chief Executive Officer, Director
  • Keith Cummings
    Chief Financial Officer
  • Lily Cheung
    Chief Human Resource Officer
  • Mike Ouimette
    General Counsel, Corporate Secretary
  • S. Mishima Gerhart
    Chief Regulatory Officer
  • Hans Hull
    Chief Business Officer
  • Minnie Kuo
    Chief Development Officer
  • Eric Lefebvre
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.